Better Medical Device Stock Right Now: Abbott Laboratories vs. Dexcom

They offer investors very different value propositions.

Why Abbott Laboratories Stock Tumbled on Thursday

Abbott Laboratories ( ABT +1.49%) more or less met analyst estimates in its first quarter, the results of which were ...

Abbott trims 2026 profit forecast on Exact deal hit, shares fall

By Siddhi Mahatole and Puyaan Singh April 16 (Reuters) - Abbott cut its annual profit forecast on Thursday due to an impact ...

Has the Abbott Laboratories Sell-Off Finally Created an Entry Point?

Whether Abbott Laboratories (NYSE: ABT) stock is at a good entry point depends on your investment horizon and tolerance for ...
MassDevice

Abbott has positive drug-eluting scaffold data

Abbott (NYSE:ABT) today shared promising 30-day results for its Esprit BTK everolimus-eluting resorbable scaffold system.

Abbott earnings beat estimates—but it was all downhill from there

Abbott Laboratories continues to grapple with falling sales in its nutrition segment.
Medical Device and Diagnostic Industry (MD+DI)

Abbott’s Mixed Q1: Strong Revenue Growth Tempered by Lowered Guidance

Abbott beats Q1 earnings but trims guidance after $21B Exact Sciences acquisition. Medical devices grow 8.5% while nutrition ...
Forbes

Abbott’s $21 Billion Exact Sciences Deal Fills Void Of Lost Covid Test Sales

Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...

Abbott hits 52-week low as Exact Sciences buyout hurts outlook (update)

Abbott (ABT) stock dips as the company trims 2026 EPS guidance to reflect its recent $21B acquisition of Exact Sciences. Read ...